Patients with TRK fusion–positive disease experienced promising survival outcomes following treatment with larotrectinib vs standard of care.

Patients with HER2-low unresectable or recurrent breast cancer in Japan could receive treatment with trastuzumab deruxtecan in the future if the newly submitted supplemental new drug application for this indication is approved.

Steven J. Chmura, MD, PhD, discussed recent findings from the phase 2R/3 NRG-BR002 trial in patients with newly diagnosed oligometastatic breast cancer.

Paolo Tarantino, MD, and Sara M. Tolaney, MD, MPH, spoke with CancerNetwork® about highlights from 2022 ASCO in breast cancer research.

Xiuning Le, MD, PhD, spoke about which patients with advanced non–small cell lung cancer with high MET-amplification could benefit most from tepotinib based on molecular markers.

In a new series from CancerNetwork®, 2 teams of fellows from leading institutions go head-to-head to debate the latest datasets and advances in acute lymphoblastic leukemia.

Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.

Benjamin Cooper, MD, discussed potential future studies exploring TAK-676 plus pembrolizumab after radiation for those with solid tumors.

Stacy A. Cohen, MD, and Mark Lewis, MD, review results from the GALAXY study on circulating tumor DNA dynamics in CRC.

Roger Li, MD, spoke about the safety profile of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer.